跳至主要内容
临床试验/NCT02247765
NCT02247765已完成3 期

Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion in Healthy, Well Perfused Subjects With the USB Pulse Oximetry Monitor Interface Cable

Medtronic - MITG2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2014年11月1日最近更新:
适应症
干预措施

试验速览

阶段
3 期
状态
已完成
入组人数
18
试验地点
2
主要终点
SpO2 Accuracy During Motion Conditions - MaxA Sensor

研究概览

简要总结

To validate the proposed claims for pulse rate and saturation accuracy in a diverse subject population during motion over a specified saturation range.

详细描述

Use an investigational oximetry system to evaluate the triggering of the "sensor off" status with marketed, off-the-shelf sensors.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Male or female of any race
  • •18-50 years old, inclusive
  • •Females: negative urine pregnancy test on the day of study participation (prior to exposure to hypoxia)
  • •Completed within the last year: physical exam by a licensed physician, physician assistant (PA), or advanced practice nurse; including a 12 lead ECG, a medical history, and blood test (complete blood count and sickle cell trait/disease screening)
  • •Meets specific demographic requirements for the monitoring device under study
  • •Willing and able to provide written informed consent
  • •Able to participate for the duration of the evaluation

排除标准

  • •A room-air baseline % modulation < 1.5% on all four fingers on the test hand
  • •Under 18 years or over 50 years of age
  • •Pregnant and/or lactating women
  • •Hypertension: on three consecutive readings, systolic pressure greater than 145 mm Hg or diastolic pressure greater than 90 mm Hg
  • •Ventricular premature complexes (VPC's) that are symptomatic or occur at a rate of more than four per minute
  • •History of seizures (except childhood febrile seizures) or epilepsy
  • •History of unexplained syncope
  • •Daily or more frequent use of anxiolytic drugs (benzodiazepines) for treatment of anxiety disorder
  • •Recent history of frequent migraine headaches: average of two or more per month over the last year
  • •Compromised circulation, injury, or physical malformation of fingers, toes, hands, ears or forehead/skull or other sensor sites which would limit the ability to test sites needed for the study. (Note: Certain malformations may still allow subjects to participate if the condition is noted and would not affect the particular sites utilized.)
  • •History of acute altitude sickness at or below moderate elevation (up to 5,000-10,000 feet) defined as three or more of the following symptoms: moderate to severe headache, general malaise, dizziness/lightheadedness, nausea/vomiting, fatigue/weakness, shortness of breath, nosebleed, persistent rapid pulse, or peripheral edema
  • •History of significant respiratory disease such as severe asthma or emphysema or sleep apnea
  • •Sickle cell disease or trait
  • •Clinically significant abnormal finding on medical history, physical examination, clinical laboratory test or ECG. Clinical significance will be assessed by the principal investigator or study physician as designated.
  • •History of stroke, transient ischemic attack or carotid artery disease
  • •History of myocardial ischemia, angina, myocardial infarction, congestive heart failure or cardiomyopathy
  • •History of chronic renal impairment
  • •Severe contact allergies to standard adhesives, latex or other materials found in pulse oximetry sensors, ECG electrodes, respiration monitor electrodes or other medical sensors
  • •Unwillingness or inability to remove colored nail polish or artificial nails from test digit(s)
  • •Unwillingness or inability to give informed consent
  • •Prior or known allergies to: lidocaine (or similar pharmacological agents, e.g., Novocain) or heparin
  • •Recent arterial cannulation (i.e., less than 30 days prior to study date)
  • •Six or more arterial cannulations of each (right & left) radial artery
  • •History of clinically significant complications from previous arterial cannulation
  • •Current use of blood thinners: prescription or daily aspirin use
  • •History of bleeding disorders or personal history of prolonged bleeding from injury.

研究组 & 干预措施

Arterial Line

Experimental

CO-Oximetry value obtained as a comparator. Obtained during motion conditions.

干预措施: Arterial line (Device)

Motion

Experimental

The subject has to perform motions during the procedure. This is to verify that device is able to read through motion.

干预措施: Motion (Device)

结局指标

主要结局

SpO2 Accuracy During Motion Conditions - MaxA Sensor

时间窗: up to 6 months

For each range specified, SpO2 accuracy of the pulse oximeter equipment is stated in terms of the Accuracy Root-Mean-Square (ARMS) difference between measured values (SpO2) and reference blood values (SaO2). The MaxA sensors has a different bandage from the MaxN sensor, and therefore a different form and fit.

SpO2 Accuracy During Motion Conditions - MaxN Sensor

时间窗: up to 6 months

For each range specified, SpO2 accuracy of the pulse oximeter equipment is stated in terms of the Accuracy Root-Mean-Square (ARMS) difference between measured values (SpO2) and reference blood values (SaO2). The MaxN sensor has a different bandage from the MaxA sensor, and therefore a different form and fit.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验